Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells
[Journal of Clinical Investigation] Upon induction of Ecotropic viral integration site 1 (Evi1) expression, mice displayed anemia, thrombocytopenia, lymphopenia, and erythroid and megakaryocyte dysplasia with a significant expansion of committed myeloid progenitor cells, resembling human myelodysplastic syndrome/myeloproliferative neoplasm–like disease.
Relationship Between Donor Source, Pre-Transplant Measurable Residual Disease, and Outcome After Allografting for Adults with Acute Myeloid Leukemia
[Leukemia] Investigators retrospectively analyzed 1265 myelodysplastic neoplasm/AML and AML patients allografted in first or second remission with an HLA-matched sibling or unrelated donor, HLA-mismatched unrelated donor, an HLA-haploidentical donor, or umbilical cord blood at a single institution.
PRMT1 Promotes the Self-Renewal of Leukemia Stem Cells by Regulating Protein Synthesis
[Advanced Science] The authors verified the critical role of protein arginine methyltransferase 1 (PRMT1) in the maintenance of chronic myeloid leukemia (CML) leukemia stem cells (LSCs). It was found that PRMT1 promoted the survival and serially plating abilities of human primary CML LSCs.
Preclinical Development of Lentiviral Vector Gene Therapy for Diamond-Blackfan Anemia Syndrome
[Molecular Therapy] To facilitate lentiviral vector design, optimize transduction and assess potential therapeutic efficacy, researchers leveraged a human cellular model of Diamond-Blackfan anemia syndrome based on heterozygous disruption of RPS19 in healthy donor CD34+ hematopoietic stem/progenitor cells.
Clinical Interrogation of TP53 Aberrations and Its Impact on Survival in Patients with Myeloid Neoplasms
[Haematologica] This retrospective analysis included patients with newly diagnosed myelodysplastic syndrome and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. They factored patient age, TP53 aberration burden, therapy intensity and use of venetoclax in the AML subgroup, and allogeneic hematopoietic stem cell transplantation to interrogate outcomes.
Clonal Hematopoiesis-Related Mutant ASXL1 Promotes Atherosclerosis in Mice via Dysregulated Innate Immunity
[Nature Cardiovascular Research] Scientists showed that hematopoietic cells harboring C-terminally truncated ASXL1 mutant accelerated the development of atherosclerosis in Ldlr–/– mice.
Efficacy and Safety of Venetoclax plus Azacitidine for Patients with Treatment-Naive High-Risk Myelodysplastic Syndromes
[Blood] This Phase Ib study investigated the safety and efficacy of venetoclax, a selective BCL-2 inhibitor, at the recommended Phase II dose, in combination with azacitidine for treatment-naive higher-risk myelodysplastic syndromes.
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
[New England Journal of Medicine] Gene therapy for hemophilia A with the use of lentiviral vector–transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in the peripheral blood.
IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies via Modulation of B-1 Cell Subsets in Murine SCD
[Blood] Investigators showed that sickle cell disease (SCD) mice had significantly enhanced type 2 T cell-independent immune responses in a manner dependent on the level of type I IFN, while maintaining similar or decreased T cell-dependent immune responses depending on the route of antigen administration.
Modus Therapeutics Initiates Phase II Study with Sevuparin for the Treatment of Chronic Kidney Disease with Anemia
[Modus Therapeutics] Modus Therapeutics announced that the first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease with associated anemia.
The START Center for Cancer Research Expands its Capabilities to Support Early-Phase Hematological Cancer Trials
[START] The START Center for Cancer Research (START) has announced the expansion of its capabilities to support early phase hematological cancer trials globally. This expansion includes the addition of leading Principal Investigators and clinical staff and growth in site capabilities.
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
[Journal of Clinical Oncology] SEQUOIA was a Phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
